^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PDE4 inhibitor

    Related drugs:
    1d
    Dose-response Study of Apremilast in Women and Men With Alcohol Use Disorder (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Yale University | Initiation date: Nov 2025 --> Mar 2026
    Trial initiation date
    3d
    A phase II clinical Trial on the efficacy and safety of TQC3721 inhalation powder (ChiCTR2500112449)
    P2, N=195, Not yet recruiting, West China Hospital, Sichuan University; Chia Tai Tianqing Pharmaceutical Group Co., Ltd
    New P2 trial
    8d
    Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis (clinicaltrials.gov)
    P=N/A, N=36, Not yet recruiting, Assiut University
    New trial
    8d
    Comparative Study of Crisaborole vs. Tacrolimus in Atopic Dermatitis (clinicaltrials.gov)
    P4, N=30, Not yet recruiting, Cairo University
    New P4 trial
    13d
    Diuretic Effect of Aminophylline and Furosemide in Adult Patients Undergoing Cardiac Surgical Procedures (clinicaltrials.gov)
    P=N/A, N=106, Recruiting, Cairo University | Not yet recruiting --> Recruiting
    Enrollment open
    15d
    Ulcerative pyoderma gangrenosum in a 78-year-old woman treated with brodalumab: A case report. (PubMed, SAGE Open Med Case Rep)
    The patient was refractory to corticosteroids, dapsone, and roflumilast, and developed recurrent Gram-negative infections. Brodalumab may offer a safe and effective treatment option in refractory pyoderma gangrenosum, particularly in patients with contraindications to conventional therapies. This case supports further evaluation of IL-17 pathway inhibition in neutrophilic dermatoses.
    Journal
    |
    IL17A (Interleukin 17A) • IL17RA (Interleukin 17 Receptor A)
    |
    roflumilast
    18d
    Diuretic Effect of Aminophylline and Furosemide in Adult Patients Undergoing Cardiac Surgical Procedures (clinicaltrials.gov)
    P=N/A, N=106, Not yet recruiting, Cairo University
    New trial
    20d
    Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis (clinicaltrials.gov)
    P1, N=16, Recruiting, Arcutis Biotherapeutics, Inc.
    New P1 trial
    21d
    A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (clinicaltrials.gov)
    P3, N=3973, Terminated, Chiesi Farmaceutici S.p.A. | Active, not recruiting --> Terminated; Strategic decision by Sponsor; not due to safety reasons
    Trial termination
    |
    roflumilast
    21d
    Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users (clinicaltrials.gov)
    P2, N=176, Completed, VA Office of Research and Development | Recruiting --> Completed | N=120 --> 176 | Trial completion date: Jun 2026 --> Oct 2025
    Trial completion • Enrollment change • Trial completion date
    |
    Eyevinal (ibudilast)
    25d
    A Clinical Study Evaluating the Pharmacokinetics and Pharmacodynamics of HSK39004 Inhalation Suspension in COPD Patients (clinicaltrials.gov)
    P2, N=12, Active, not recruiting, Haisco Pharmaceutical Group Co., Ltd.
    New P2 trial